| Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. | |
| | |
MedLine Citation:
|
PMID: 20484480 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Long-term data are missing in GH-treated acute lymphoblastic leukemia (ALL) patients. GH therapy may result in poorer outcome regarding cardiovascular (CV) and particularly cardiac effects than in patients with hypothalamic-pituitary disease. OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2). DESIGN AND SETTING: We conducted a 5- and 8-yr open nonrandomized prospective study in a university hospital clinic. STUDY PARTICIPANTS: Two groups of GH-deficient ALL patients (aged 25 yr; range 19-32 yr) and matched population controls participated. INTERVENTIONS: One ALL group (n=16) received GH for 5 yr, and the other ALL group (n=13) did not receive GH therapy. MAIN OUTCOME MEASURES: We evaluated the prevalence of CV risk factors and metabolic syndrome (International Diabetes Federation consensus), cardiac function (echocardiography), and quality of life and physical activity questionnaires. RESULTS: In comparison with 8 yr without, 5 yr with GH therapy resulted in significant positive changes in plasma glucose (-0.5 vs. 0.6 mmol/liter, P=0.002), apolipoprotein B/apolipoprotein A1 ratio (-0.1 vs. 0.0, P=0.03), and high-density lipoprotein-cholesterol (0.20 vs.-0.01 mmol/liter, P=0.008) and a significant reduction in the prevalence of metabolic syndrome (P=0.008). No significant difference in the left-ventricular systolic function or in physical activity and quality of life was recorded before and after 5 or 8 yr, respectively (all P>0.3). CONCLUSION: GH therapy reduced the CV risk in this young ALL population but resulted in no clear benefit or deterioration in cardiac function. |
| | |
Authors:
|
Cecilia Follin; Ulf Thilén; Kai Osterberg; Jonas Björk; Eva Marie Erfurth |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-05-19 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 95 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-05 Completed Date: 2010-08-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 3726-35 Citation Subset: AIM; IM |
Affiliation:
|
Department of Endocrinology, Lund and Malmö University Hospital, Lund University, SE-221 85 Lund, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Body Composition Body Mass Index Cardiovascular Diseases / etiology Child Female Heart Function Tests Human Growth Hormone / deficiency, therapeutic use* Humans Male Motor Activity Patient Selection Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*, psychology Prospective Studies Quality of Life / psychology* Questionnaires Risk Risk Factors Social Support Statistics, Nonparametric Survivors |
| Chemical | |
Reg. No./Substance:
|
12629-01-5/Human Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.
Next Document: Analysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism.